SG11201402112RA - Use of humanized mice to determine toxicity - Google Patents

Use of humanized mice to determine toxicity

Info

Publication number
SG11201402112RA
SG11201402112RA SG11201402112RA SG11201402112RA SG11201402112RA SG 11201402112R A SG11201402112R A SG 11201402112RA SG 11201402112R A SG11201402112R A SG 11201402112RA SG 11201402112R A SG11201402112R A SG 11201402112RA SG 11201402112R A SG11201402112R A SG 11201402112RA
Authority
SG
Singapore
Prior art keywords
humanized mice
determine toxicity
toxicity
humanized
mice
Prior art date
Application number
SG11201402112RA
Inventor
Salim Bouguermouh
Maroun Khoury
Qingfeng Chen
Jianzhu Chen
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of SG11201402112RA publication Critical patent/SG11201402112RA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/10—Animals modified by protein administration, for non-therapeutic purpose
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
SG11201402112RA 2011-12-06 2012-12-05 Use of humanized mice to determine toxicity SG11201402112RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161567466P 2011-12-06 2011-12-06
PCT/US2012/067983 WO2013086019A1 (en) 2011-12-06 2012-12-05 Use of humanized mice to determine toxicity

Publications (1)

Publication Number Publication Date
SG11201402112RA true SG11201402112RA (en) 2014-09-26

Family

ID=48574837

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402112RA SG11201402112RA (en) 2011-12-06 2012-12-05 Use of humanized mice to determine toxicity

Country Status (5)

Country Link
US (1) US20150007357A1 (en)
EP (1) EP2788758A4 (en)
CN (1) CN104160272A (en)
SG (1) SG11201402112RA (en)
WO (1) WO2013086019A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180153145A1 (en) * 2015-05-22 2018-06-07 Champions Oncology, Inc. Humanized mice and uses thereof
US20180289840A1 (en) * 2015-05-24 2018-10-11 Central Institute For Experimental Animals Method for Evaluating Hematological Toxicity of Drug Under Evaluation, and Model for Evaluating Hematological Toxicity of Drug Under Evaluation
WO2017049002A1 (en) * 2015-09-15 2017-03-23 Massachusetts Institute Of Technology A humanized mouse model of de novo human acute myeloid leukemia with a matching human immune system
US9928025B2 (en) * 2016-06-01 2018-03-27 Ford Global Technologies, Llc Dynamically equalizing receiver
FI3612840T3 (en) * 2017-04-17 2023-03-22 Method of determining toxicity of an immunomodulatory drug for use in humans
US20210153484A1 (en) * 2018-04-09 2021-05-27 The Wistar lnstitute Humanized Mouse Model
WO2020041174A1 (en) * 2018-08-20 2020-02-27 The Jackson Laboratory Method of determining toxicity of an immunomodulatory drug
WO2020068615A1 (en) * 2018-09-24 2020-04-02 Albert Einstein College Of Medicine Interleukin-8 for maintenance of human acute myeloid leukemia and myelodysplastic syndrome and uses thereof
CN110940812A (en) * 2018-09-25 2020-03-31 上海恒润达生生物科技有限公司 Detection method for evaluating immune toxicity after CART cell infusion
WO2021097203A1 (en) * 2019-11-15 2021-05-20 Board Of Regents, The University Of Texas System Humanized mouse model with human immune system
CN112042597B (en) * 2020-07-22 2022-04-29 南京普恩瑞生物科技有限公司 Construction method of double humanized tumor xenograft model

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9812364A (en) * 1997-09-23 2000-09-19 Zeneca Ltd Compound, use thereof, pharmaceutical composition, amide derivative, and process for the preparation of an amide derivative or a pharmaceutically acceptable salt or in vivo cleavable ester thereof
US6509514B1 (en) * 2000-03-17 2003-01-21 Kmt Hepatech, Inc. Chimeric animal model susceptible to human hepatitis C virus infection
EP1907002A2 (en) * 2005-07-11 2008-04-09 Macrogenics, Inc. Methods of treating autoimmune disease using humanized anti-cd16a antibodies
EP1878342A1 (en) * 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
WO2009146029A1 (en) * 2008-03-31 2009-12-03 Gerold Feuer An animal model and method of treatment for human t cell leukemia
WO2009154995A2 (en) * 2008-05-27 2009-12-23 Kyowa Hakko Kirin Co., Ltd. Interleukin 10 receptor (il-10r) antibodies and methods of use
EP2449094A4 (en) * 2009-06-29 2013-07-10 Qingfeng Chen Methods of producing humanized non-human mammals
AU2010303737B2 (en) * 2009-10-06 2014-05-29 Institute For Research In Biomedicine (Irb) Genetically modified mice and engraftment

Also Published As

Publication number Publication date
WO2013086019A1 (en) 2013-06-13
EP2788758A1 (en) 2014-10-15
CN104160272A (en) 2014-11-19
US20150007357A1 (en) 2015-01-01
EP2788758A4 (en) 2015-06-10

Similar Documents

Publication Publication Date Title
HK1244183A1 (en) Deuterated derivatives of ivacaftor
SG11201402112RA (en) Use of humanized mice to determine toxicity
EP2756410A4 (en) Geo-migration of user state
HUE047354T2 (en) Deuterated derivatives of ivacaftor
BR112014003878A2 (en) synthesis of r-biphenylalaninol
EP2764325A4 (en) Using videogrammetry to fabricate parts
PL2690985T3 (en) Piece of furniture
HK1192323A1 (en) Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles glu-
EP2773262A4 (en) Evaluation of cardiac structure
HK1203355A1 (en) Uses of 4-desferrithiocin analogs 4-
PL2753330T3 (en) Therapeutic uses of ectoin
EP2709999A4 (en) Quinazoline-7-ether compounds and methods of use
PL2691585T3 (en) Improvements relating to construction
HK1199040A1 (en) Use of antibody
PL2583571T3 (en) Improvements relating to chaps
ZA201308101B (en) Diagnostic use of prosomatostatin
GB2488866B (en) Use of GPS to detect repetitive motion
EP2684869A4 (en) Preparation of 3-mercaptopropionates
EP2680843A4 (en) Derivatives of pyrazole-substituted amino-heteroaryl compounds
ZA201307570B (en) Use of dithine-tetracarboximides as bird repellent
PL2709584T3 (en) Sensory use of 6-cyclopentylidenehexane derivatives
GB201211721D0 (en) Improvements is or relating to urolgical catheters
FI20110263L (en) Kettlebell to share
UA23645S (en) SET OF FURNITURE
UA22461S (en) DETAIL OF SHAPED COMPRESSION-COLLECTING